Drug General Information
Drug ID
D0Y4BL
Former ID
DIB020109
Drug Name
JNJ-28312141
Synonyms
JNJ 28312141
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530495]
Structure
Download
2D MOL
Formula
C26H32N6O2
InChI
InChI=1S/C26H32N6O2/c1-31(2)17-24(33)32-12-10-18(11-13-32)20-8-9-23(22(14-20)19-6-4-3-5-7-19)30-26(34)25-28-16-21(15-27)29-25/h6,8-9,14,16,18H,3-5,7,10-13,17H2,1-2H3,(H,28,29)(H,30,34)
InChIKey
GUBJNPWVIUFSTR-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Trk receptor Target Info Inhibitor [530495]
Mast/stem cell growth factor receptor Target Info Inhibitor [530495]
Lck tyrosine kinase Target Info Inhibitor [530495]
mRNA of Colony stimulating factor-1 receptor Target Info Inhibitor [531679]
FL cytokine receptor Target Info Inhibitor [530495]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Hematopoietic cell lineage
Melanogenesis
Pathways in cancer
Acute myeloid leukemia
Central carbon metabolism in cancerhsa04064:NF-kappa B signaling pathway
Osteoclast differentiation
Natural killer cell mediated cytotoxicity
T cell receptor signaling pathway
HTLV-I infection
Primary immunodeficiencyhsa04060:Cytokine-cytokine receptor interaction
Transcriptional misregulation in cancer
Central carbon metabolism in cancer
NetPath Pathway IL3 Signaling Pathway
IL4 Signaling Pathway
KitReceptor Signaling PathwayNetPath_11:TCR Signaling Pathway
IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
Notch Signaling Pathway
PANTHER Pathway Parkinson disease
T cell activation
Pathway Interaction Database C-MYB transcription factor network
Signaling events mediated by Stem cell factor receptor (c-Kit)nfkappabatypicalpathway:Atypical NF-kappaB pathway
Glypican 1 network
TCR signaling in na&#xef
Signaling events mediated by PTP1B
IL12-mediated signaling events
Regulation of p38-alpha and p38-beta
TCR signaling in na&#xef
Thromboxane A2 receptor signaling
SHP2 signaling
IL2-mediated signaling events
CXCR4-mediated signaling events
Class I PI3K signaling events
IL2 signaling events mediated by PI3K
amb2 Integrin signaling
EPHA forward signaling
PDGFR-beta signaling pathway
IL2 signaling events mediated by STAT5
Ephrin B reverse signaling
Alpha-synuclein signalingptp1bpathway:Signaling events mediated by PTP1B
Signaling events mediated by TCPTP
Integrins in angiogenesis
Reactome ARMS-mediated activation
NGF-independant TRKA activation
PI3K/AKT activationR-HSA-1257604:PIP3 activates AKT signaling
Regulation of KIT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascadeR-HSA-114604:GPVI-mediated activation cascade
PIP3 activates AKT signaling
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
PECAM1 interactions
DAP12 signaling
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
CD28 dependent Vav1 pathway
CTLA4 inhibitory signaling
PD-1 signaling
Interleukin-2 signaling
WikiPathways MAPK Signaling Pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
NGF signalling via TRKA from the plasma membraneWP304:Kit receptor signaling pathway
Differentiation Pathway
Signaling by SCF-KIT
PIP3 activates AKT signaling
Cardiac Progenitor Differentiation
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBaseWP61:Notch Signaling Pathway
Interferon type I signaling pathways
IL-2 Signaling Pathway
Inflammatory Response Pathway
DAP12 interactions
Host Interactions of HIV factors
T-Cell Receptor and Co-stimulatory Signaling
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
TCR signaling
Costimulation by the CD28 family
References
Ref 530495JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
Ref 530495JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
Ref 531679Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.